PHILADELPHIA-Tuesday 28 July 2020 [ AETOS Wire ]
(BUSINESS WIRE) -- PCI Pharma Services (PCI),
a leading pharmaceutical and biopharmaceutical global outsourcing
solutions provider, today announced a significant milestone in its
global clinical footprint with the creation of a new Clinical Center of
Excellence (COE) in Western Europe at its Berlin location, a major
investment that will represent a new flagship site for customers. This
is part of PCI’s global strategy to expand its clinical supply-chain
network into continental Europe to complement offerings available at its
UK and Ireland sites. The COE is expected to be completed in January
2021.
“With
this expansion, our Berlin Clinical Center of Excellence will address
the needs of European and global clients,” said Brian Keesee, vice
president and general manager, Global Clinical Operations and Supply,
PCI Pharma Services. “Berlin is an excellent logistical hub that will
serve as a proactive solution to Brexit, ensuring there are no gaps in
the supply chain and our clients conducting clinical trials in all parts
of Europe continue to be served.”
The
Berlin COE will include 17,000 square feet of space dedicated to
primary and secondary packaging, storage of pharmaceutical and
biopharmaceutical therapies at all temperature ranges, and distribution.
This capacity is well positioned to service the EU-based clinical
trials ecosystem, which currently has more than 38,100 active trials
sites throughout the 27-member countries and is second only to the
United States for such research. Of the EU countries, France and Germany
rank first and second, with 7,370 and 4,418 active trial sites,
respectively.i
“Our
strategy has always been to increase the capacity and capabilities of
our clinical trial services network, and with the acquisition of
Bellwyck Pharma Services earlier this year, we are taking the next step
to enhance our capabilities at our new Berlin facility to support the
growing clinical trial market in Europe and beyond,” said Salim Haffar,
chief executive officer, PCI Pharma Services. “This investment will
provide clients with global clinical trial solutions for their
life-changing medicines, ensuring continuity of patient supply to match
growing market demands.”
About PCI Pharma Services
The
global healthcare industry trusts PCI for the drug development
solutions that increase their products’ speed to market and
opportunities for commercial success. Only PCI brings the proven
experience that comes with more than 50 successful product launches a
year and over five decades in the healthcare business. Leading
technology and continued investment enable us to address global
development needs throughout the product life cycle — from Phase I
Clinical trials through commercialization and ongoing supply. Our
clients view us as an extension of their business and a collaborative
partner, with the shared goal of improving patients’ lives. For more
information, please visit www.pci.com or follow us on Twitter at @PCI_Social.
___________________
i ClinicalTrials.gov Web site. Advanced Search of Trial Status Active, not recruiting; Recruiting; Enrolling by invitation. Bethesda (MD): National Library of Medicine (US). Available: https://clinicaltrials.gov/ct2/results/map?recrs=adf&map=. Accessed 2020 July 27.
i ClinicalTrials.gov Web site. Advanced Search of Trial Status Active, not recruiting; Recruiting; Enrolling by invitation. Bethesda (MD): National Library of Medicine (US). Available: https://clinicaltrials.gov/ct2/results/map?recrs=adf&map=. Accessed 2020 July 27.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200728005211/en/
Contacts
Bailey Watroba, WE Communications
bwatroba@we-worldwide.com / +1-617-234-4110
